We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

CytoDyn, Investors End Chancery Director Options Suit

Law360 (January 10, 2019, 8:40 PM EST) -- Biotechnology company CytoDyn Inc. agreed to pay a $50,000 attorney fee in a Delaware Chancery Court settlement approved on Thursday that ended a stockholder challenge to excess stock options paid to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.